deaths (OS)

metastatic (mCRPC) - 1st line (L1) castration-resistant prostate cancer (CRPC) metastatic (mCRPC) - 1st line (L1)

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus androgen deprivation therapy (ADT)
apalutamide plus ADT vs. androgen deprivation therapy (ADT) 1 certainty unassessablestatistically conclusive-30%